{
  "pmcid": "6018837",
  "sha256": "f016ce67378709288db63f4c7c96c82357fc983d6ce346a3e8d59776ab2bf0c9",
  "timestamp_utc": "2025-11-10T00:00:12.547394+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.188477184294307,
    "reading_ease": 35.653440926777535,
    "word_count": 257
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Interspinous Process Devices vs. Decompressive Surgery for Lumbar Stenosis"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised 1:1 to IPD or SDS"
      },
      "Participants": {
        "score": 2,
        "evidence": "This multicenter, international, open-label, randomised controlled trial enrolled 163 patients from 19 sites across 10 countries"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised 1:1 to IPD or SDS"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the safety and noninferiority of a minimally invasive percutaneous IPD compared to standalone decompressive surgery (SDS)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the mean percentage change in Zurich Claudication Questionnaire (ZCQ) physical function from baseline to 12 months."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "randomisation implemented via an electronic data capture system using blinded blocks"
      },
      "Blinding": {
        "score": 3,
        "evidence": "open-label"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "enrolled 163 patients from 19 sites across 10 countries between January 2010 and April 2014"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "At 12 months, both groups showed significant improvement in ZCQ physical function (IPD: −32.3 ± 32.1, SDS: −37.5 ± 22.8, both P < .001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar between groups, with 33.8% of IPD and 33.3% of SDS patients experiencing at least one serious adverse event."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The study was registered at ClinicalTrials.gov (NCT00905359)"
      },
      "Funding": {
        "score": 1,
        "evidence": "funded by Medtronic Spinal and Biologics"
      }
    },
    "total_score": 21,
    "max_score": 25
  }
}